NCT01938625 / 2013-002726-23: A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation |
|
|
| Completed | 2 | 35 | Europe | Simeprevir, Daclatasvir, Ribavirin, Cyclosporine, Tacrolimus | Janssen R&D Ireland | Hepatitis C, Chronic | 04/15 | 07/15 | | |